We are live on ! Find out more
PRVL

Prevail Therapeutics Inc. Common Stock
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

Back to rankings

76 hedge funds and large institutions have $302M invested in Prevail Therapeutics Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 11

28% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 18

13% more funds holding

Funds holding: 67 → 76 (+9)

28% less capital invested

Capital invested by funds: $421M → $302M (-$119M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
76
Holders Change
+9
Holders Change %
+13.43%
% of All Funds
1.53%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
20
Increased
23
Reduced
18
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$16.6M
2
HighTower Advisors
HighTower Advisors
Illinois
+$15.2M
3
BlackRock
BlackRock
New York
+$7.5M
4
Morgan Stanley
Morgan Stanley
New York
+$3.66M
5
Bank of America
Bank of America
North Carolina
+$3.05M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$15.3M
2
RCM
RA Capital Management
Massachusetts
-$7.77M
3
EC
EcoR1 Capital
California
-$5.47M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$4.35M
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$914K
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
26
Squarepoint
New York
$724K +$232K +17,280 +32%
UBS Group
27
UBS Group
Switzerland
$694K -$63.4K -4,727 -6%
Goldman Sachs
28
Goldman Sachs
New York
$575K +$323K +24,067 +74%
GCP
29
GSA Capital Partners
United Kingdom
$540K +$711K +53,018 New
AS
30
Altshuler Shaham
Israel
$529K – – –
JP Morgan Chase
31
JP Morgan Chase
New York
$463K +$98.7K +7,354 +19%
Two Sigma Investments
32
Two Sigma Investments
New York
$452K +$284K +21,149 +91%
MAM
33
Martingale Asset Management
Massachusetts
$404K +$531K +39,608 New
WC
34
Wexford Capital
Florida
$386K +$509K +37,963 New
Allianz Asset Management
35
Allianz Asset Management
Germany
$366K -$99.9K -7,447 -17%
Charles Schwab
36
Charles Schwab
California
$339K -$23.1K -1,724 -5%
California Public Employees Retirement System
37
California Public Employees Retirement System
California
$335K +$17.4K +1,300 +4%
Barclays
38
Barclays
United Kingdom
$322K +$194K +14,493 +85%
SO
39
STRS Ohio
Ohio
$316K – – –
Two Sigma Advisers
40
Two Sigma Advisers
New York
$304K +$401K +29,900 New
Ensign Peak Advisors
41
Ensign Peak Advisors
Utah
$286K +$378K +28,143 New
AllianceBernstein
42
AllianceBernstein
Tennessee
$238K -$12.1K -900 -4%
Los Angeles Capital Management
43
Los Angeles Capital Management
California
$223K +$18.1K +1,350 +7%
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
$221K – – –
Dimensional Fund Advisors
45
Dimensional Fund Advisors
Texas
$219K +$289K +21,568 New
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$217K +$107 +8 +0%
TI
47
Trexquant Investment
Connecticut
$203K +$267K +19,910 New
VEA
48
Virtus ETF Advisers
New York
$201K -$36K -2,687 -12%
First Trust Advisors
49
First Trust Advisors
Illinois
$176K +$232K +17,304 New
CCM
50
CAAS Capital Management
New York
$175K +$231K +17,200 New
1
2
3 4

PRVL Hedge Fund Activity: Q3 2020 in Review

76 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q3 2020, worth a combined $302M — down 28% from $421M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new PRVL positions and 11 closed out — a net gain of 9 holders — while 23 added to existing stakes and 18 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $16.6M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $15.3M sold.

  • 76 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q3 2020, up from 67 in Q2 2020.
  • Funds reported $302M of Prevail Therapeutics Inc. Common Stock stock for Q3 2020, down 28% quarter-over-quarter.
  • 20 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q3 2020 and 11 closed out, a net change of +9 holders.
  • The largest Prevail Therapeutics Inc. Common Stock buyer in Q3 2020 was Citadel Advisors, an estimated $16.6M added.
  • The largest Prevail Therapeutics Inc. Common Stock seller in Q3 2020 was Avidity Partners Management, an estimated $15.3M sold.

Based on aggregated 13F filings for Q3 2020.